Journal of Antimicrobial Chemotherapy, Vol 40, 885-888, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
SE Hoffner, L Gezelius and B Olsson-Liljequist
The increasing incidence of drug-resistant Mycobacterium tuberculosis
necessitates therapeutic alternatives. The in-vitro activities of seven
fluoroquinolone and macrolide compounds were tested against 23 clinical
isolates of M. tuberculosis, including 17 multidrug-resistant strains.
Sparfloxacin was the most active fluoroquinolone, with MICs of < or = 1
mg/L for all tested strains, followed by levofloxacin and ciprofloxacin.
Trovafloxacin had no inhibitory activity at the concentrations tested. The
MICs of the macrolides were generally higher, clarithromycin being the most
active with MICs of < or = 8 mg/L for eight of the 23 strains.
ORIGINAL ARTICLES
In-vitro activity of fluorinated quinolones and macrolides against drug- resistant Mycobacterium tuberculosis
Department of Bacteriology, Swedish Institute for Infectious Disease Control, Stockholm.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Devasia, A. Blackman, T. Gebretsadik, M. Griffin, A. Shintani, C. May, T. Smith, N. Hooper, F. Maruri, J. Warkentin, et al. Fluoroquinolone Resistance in Mycobacterium tuberculosis: The Effect of Duration and Timing of Fluoroquinolone Exposure Am. J. Respir. Crit. Care Med., August 15, 2009; 180(4): 365 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Devasia, A. Blackman, C. May, S. Eden, T. Smith, N. Hooper, F. Maruri, C. Stratton, A. Shintani, and T. R. Sterling Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance J. Antimicrob. Chemother., June 1, 2009; 63(6): 1173 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Andini and K. A. Nash Intrinsic Macrolide Resistance of the Mycobacterium tuberculosis Complex Is Inducible. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2560 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Falzari, Z. Zhu, D. Pan, H. Liu, P. Hongmanee, and S. G. Franzblau In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1447 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Di Perri and S. Bonora Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J. Antimicrob. Chemother., September 1, 2004; 54(3): 593 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Garcia-Garcia, J. Galvez, J.-V. de Julian-Ortiz, R. Garcia-Domenech, C. Munoz, R. Guna, and R. Borras New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method J. Antimicrob. Chemother., January 1, 2004; 53(1): 65 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Alvirez-Freites, J. L. Carter, and M. H. Cynamon In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosis Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1022 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. V. Piddock and V. Ricci Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv J. Antimicrob. Chemother., December 1, 2001; 48(6): 787 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. A. Linde, S. E. Hoffner, E. Refai, and M. Andersson In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis J. Antimicrob. Chemother., May 1, 2001; 47(5): 575 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bosne-David, V. Barros, S. C. Verde, C. Portugal, and H. L. David Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors J. Antimicrob. Chemother., September 1, 2000; 46(3): 391 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ruiz-Serrano, L. Alcalá, L. Martínez, M. Díaz, M. Marín, M. J. González-Abad, and E. Bouza In Vitro Activities of Six Fluoroquinolones against 250 Clinical Isolates of Mycobacterium tuberculosis Susceptible or Resistant to First-Line Antituberculosis Drugs Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2567 - 2568. [Abstract] [Full Text]
|
|
|
|
|
|
H. Tomioka, K. Sato, H. Kajitani, T. Akaki, and S. Shishido Comparative Antimicrobial Activities of the Newly Synthesized Quinolone WQ-3034, Levofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium Complex Antimicrob. Agents Chemother., February 1, 2000; 44(2): 283 - 286. [Abstract] [Full Text]
|
|
|
|
|
|
H. Tomioka, K. Sato, T. Akaki, H. Kajitani, S. Kawahara, and M. Sakatani Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafloxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium Complex Antimicrob. Agents Chemother., December 1, 1999; 43(12): 3001 - 3004. [Abstract] [Full Text]
|
|